Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma

References

• Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis 2017;9:448–51.
   PubMed Web of Science ®Google Scholar
• Fischer PM, Endicott J, Meijer L. Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res 2003;5:235–48.
   PubMedGoogle Scholar
• Idowu MA. Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. a role for systems biology approach in drug development. Part II—CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs. Biotechnol Biotechnol Equip 2012;26:2712–5.
   Web of Science ®Google Scholar
• Dictor M, Ehinger M, Mertens F, et al. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 1999;112:S40–S52.
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131–49.
   PubMed Web of Science ®Google Scholar
• Ma T, Van Tine BA, Wei Y, et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000;14:2298–313.
   PubMed Web of Science ®Google Scholar
• Flores O, Wang Z, Knudsen KE, et al. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 2010;151:896–908.
   PubMed Web of Science ®Google Scholar
• De Boer L, Oakes V, Beamish H, et al. Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene 2008;27:4261–8.
   PubMed Web of Science ®Google Scholar
• Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776–86.
   PubMed Web of Science ®Google Scholar
• Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297–300.
   PubMed Web of Science ®Google Scholar
• Akli S, Van Pelt CS, Bui T, et al. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res 2011;71:3377–86.
   PubMed Web of Science ®Google Scholar
• Cam WR, Masaki T, Shiratori Y, et al. Activation of cyclin E-dependent kinase activity in colorectal cancer. Dig Dis Sci 2001;46:2187–98.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Monden T, Miyoshi H, et al. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int J Oncol 1998;13:233–9.
   PubMed Web of Science ®Google Scholar
• Juric V, Murphy B. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Cancer Drug Resist 2020;3:48–62.
   PubMedGoogle Scholar
• Wang J, Yang T, Xu G, et al. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl Oncol 2016;9:548–56.
   PubMed Web of Science ®Google Scholar
• Riess C, Irmscher N, Salewski I, et al. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology? Cancer Metastasis Rev 2021;40:153–71.
   PubMed Web of Science ®Google Scholar
• Desai BM, Villanueva J, Nguyen T-TK, et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLOS One 2013;8:e59588.
   PubMed Web of Science ®Google Scholar
• Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565–76.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Chng WJ, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 2015;125:443–8.
   PubMed Web of Science ®Google Scholar
• Villa E, Piscaglia F, Geva R, et al. Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients. J Clin Oncol 2020;38:e16711.
   Web of Science ®Google Scholar
• Lin S-F, Lin J-D, Hsueh C, et al. Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocr Relat Cancer 2018;25:853–64.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Caldon EC, Tilley W, et al. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem 2019;62:4233–51.
   PubMed Web of Science ®Google Scholar
• Frame S, Saladino C, MacKay C, et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLOS One 2020;15:e0234103.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243–50.
   PubMed Web of Science ®Google Scholar
• Sielecki TM, Johnson TL, Liu J, et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg Med Chem Lett 2001;11:1157–60.
   PubMed Web of Science ®Google Scholar
• Shewchuk L, Hassell A, Wisely B, et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000;43:133–8.
   PubMed Web of Science ®Google Scholar
• Abdel Gawad NM, Georgey HH, Youssef RM, et al. Synthesis and antitumor activity of some 2,3-disubstituted quinazolin-4(3H)-ones and 4,6-disubstituted-1,2,3,4-tetrahydroquinazolin-2H-ones. Eur J Med Chem 2010;45:6058–67.
   PubMed Web of Science ®Google Scholar
• Gatadi S, Pulivendala G, Gour J, et al. Synthesis and evaluation of new 4(3H)-quinazolinone derivatives as potential anticancer agents. J Mol Struct 2020;1200:127097.
   Web of Science ®Google Scholar
• ShaguftaAhmad I. An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. Medchemcomm 2017;8:871–85.
   PubMed Web of Science ®Google Scholar
• Abbas SE, Barsoum FF, Georgey HH, et al. Synthesis and antitumor activity of certain 2,3,6-trisubstituted quinazolin-4(3H)-one derivatives. Bull Fac Pharm Cairo Univ 2013;51:273–82.
   Google Scholar
• El Sayed NA, Eissa AA, El Masry GF, et al. Discovery of novel quinazolinones and their acyclic analogues as multi-kinase inhibitors: design, synthesis, SAR analysis and biological evaluation. RSC Adv 2016;6:111767–86.
   Google Scholar
• Yang Y, Shang P, Cheng C, et al. Novel N-phenyl dichloroacetamide derivatives as anticancer reagents: design, synthesis and biological evaluation. Eur J Med Chem 2010;45:4300–6.
   PubMed Web of Science ®Google Scholar
• Alqasoumi SI, Al-Taweel AM, Alafeefy AM, et al. Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents. Eur J Med Chem 2010;45:738–44.
   PubMed Web of Science ®Google Scholar
• Guo W, Miao Z, Sheng C, et al. Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I. Eur J Med Chem 2010;45:2223–8.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liang P, Rashid H. u, et al. Design, synthesis, and biological evaluation of matrine derivatives possessing piperazine moiety as antitumor agents. Med Chem Res 2019;28:1618–27.
   Web of Science ®Google Scholar
• Aaglawe J, Dhule S, Bahekar SS, et al. Synthesis and antibacterial activity of some oxazolone derivatives. J Korean Chem Soc 2003;47:133–136.
   Google Scholar
• Abbas S, Gawad N, Georgey HH, et al. New quinazolinone derivatives: synthesis, anti-inflammatory and antitumor activities. IntJ ChemTech Res 2010;2:1560–1578.
   Google Scholar
• Georgey H, Abdel-Gawad N, Abbas S. Synthesis and anticonvulsant activity of some quinazolin-4-(3H)-one derivatives. Molecules 2008;13:2557–69.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Develop Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–66.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827–33.
   PubMed Web of Science ®Google Scholar
• Pollack A, Ciancio G, Chapter 3: cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. In: Darzynkiewicz Z, Crissman HA, editors. Methods in cell biology. San Diego: Academic Press; 1990:19–24.
   Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhao H, Wang Y, et al. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. Bioorg Med Chem Lett 2018;28:3385–90.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.rcsb.org/ [last accessed 1 Aug 2021].
   Google Scholar
• SwissADME. Available from: http://www.swissadme.ch/index.php [last accessed 15 Jun 2021].
   Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model 2014;54:3284–301.
   PubMed Web of Science ®Google Scholar
• NIH Developmental Therapeutics Program. Available from: http://dtp.cancer.gov [last accessed 6 Jun 2020].
   Google Scholar
• Chohan TA, Qian H, Pan Y, et al. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. Curr Med Chem 2015;22:237–63.
   PubMed Web of Science ®Google Scholar
• Faber AC, Chiles TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle 2007;6:2982–9.
   PubMed Web of Science ®Google Scholar
• Vulpetti A, Pevarello P. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes. Curr Med Chem Anticancer Agents 2005;5:561–73.
   PubMedGoogle Scholar
• Martin MP, Endicott JA, Noble MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem 2017;61:439–52.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105–27.
   PubMed Web of Science ®Google Scholar